

TABLE I. Hematological and Biochemical Values and γ -Globin Chain Percentages

Patient	I ₁	II ₁	II ₂
Sex/age (years)	F/40	M/18	M/16
Hb g/dl	9.7	11.1	10.1
PCV l/l	0.305	0.32	0.36
RBC 10 ¹² /l	4.59	5.26	5.2
MCV fl	64	61	70
MCH pg	17	19.8	20
Hb A ₂ %	5.6	5.8	5.3
Hb F %	0.9	1.1	1.6
γ^T %	57.5	44.5	41.2
γ^L %	16.5	17.4	17.7
γ %	26	38.1	41.1

Alleles" [1]. The authors report the frameshift CD 11 (–T) β -thalassemia mutation in a father and 2 children of Mexican mestizo lineage and in one of them, this mutation is associated with the –28 A \rightarrow C β -thalassemia mutation, producing a picture of β -thalassemia major. Moreover, the authors indicate that the frameshift CD 11 (–T) mutation has not been reported in any other population. In this sense, in a study of 141 β -thalassemia alleles we found the frameshift CD 11 (–T) allele in a family (mother, I₁, and 2 children, II₁ and II₂) from Cáceres (Extremadura, western Spain) [2]. In this family the frameshift CD 11 (–T) allele was linked to the same haplotype (– + + – – + + –), analyzing the following polymorphic sites: *HincII* 5' to the ϵ gene, *HindIII* in the IVS of γ^G and γ^A genes, *HincII* in the $\psi\beta$ gene and 3' to it, *AvaII* site in the IVS-2 of the β gene, and *HpaI* and *BamHI* 3' to the β gene.

The 3 patients were diagnosed with heterozygous β^0 -thalassemia with high HbA₂, a clinical picture more severe than β -thalassemia minor. The study by Southern blot of α genes proved the existence of four genes α .

The hematological and biochemical values and the γ -globin chain percentage are shown in Table I. The molecular identification of the β -thalassemia allele was performed by direct sequencing of amplified β -gene DNA, because the lesion had not been detected by PCR-ARMS studying 24 known β -thalassemia alleles.

The family comes from Cáceres (Extremadura, western Spain). Many of the men who went to America in the fifteenth and sixteenth centuries came from this region [2]. Due to this fact, it would be interesting to pursue more studies in order to know if the real origin of this mutation is proper to the Mexican etnia or has its origin in Spain, where it has been proved that β -thalassemia is relatively frequent [3].

ACKNOWLEDGMENTS

The authors thank T.H.J. Huisman for DNA sequencing.

A. VILLEGAS
G. MARTIN
F.A. GONZALEZ
J. SANCHEZ

Servicio de Hematología y Hemoterapia, Hospital Universitario San Carlos, Madrid, and Servicio de Hematología, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain

REFERENCES

1. Perea FJ, Esparza MA, Villalobos-Arambula AR, Ibarra B, Old JM: Haplotype analysis of the Mexican frameshift CD (–T) and –28 A \rightarrow C β -thalassemia alleles. *Am J Hematol* 51:240–242, 1996.

2. Ropero P, Sánchez J, González FA, Armada B, Benito A, Caldeira A, Martín G, Villegas A: Heterogeneidad molecular de la β talasemia. *Sangre (Barc)* 39:365–368, 1994.
3. Calero F, Villegas A, Porres A, Valverde F, del Potro E, Sánchez P, Luque JM, Espinos D: Hematologic data in 825 cases of β -thalassemia trait in Spain. *Nouv Rev Fr Hematol* 32:265–270, 1990.

Reply to "Frameshift Cd 11 (–T) β -Thalassemia Mutation"

To the Editor: In regard to the letter by Villegas et al. about our article in the *American Journal of Hematology* [1], I regret not including the paper by Ropero et al. [2]. However, this letter gives us the opportunity to make some comments. In the original paper [2], the Cd 11 (–T) mutation was found in 1 of 60 studied β -thalassemia patients (67 chromosomes analyzed), in whom eight different alleles were found, with three alleles constituting almost 90% of the analyzed chromosomes (IVS1:1 G \rightarrow A, Cd 39 C \rightarrow T, and IVS1:6 T \rightarrow C). In their letter, Villegas et al. report additional studies on 74 chromosomes without finding the mutation in them, thus indicating that Cd 11 (–T) is a rare mutation in this area. The data about β -haplotypes referred to in that letter are very interesting, because Cd 11(–T) is the same haplotype found in our patient; however, since this haplotype was also found with β^A chromosomes in our Mestizo population, the possibility that the mutation appeared in both countries at different times cannot be ruled out. This could be posteriorly investigated by the recently discovered polymorphisms surrounding the β -globin gene [3]. Moreover, it is very interesting that the 3 Cd 11 (–T) carriers from Spain and at least 1 of the 2 carriers in our family [1] had a clinical picture more severe than the common β -thalassemia heterozygotes, which apparently cannot be explained by the mutation per se. The possibility that in both families the Cd 11 (–T) mutation is associated with an additional pathology, making the clinical picture more severe, is also a matter of further investigation, and these data could also give us more information about the origin of the mutation.

BERTHA IBARRA
ALMA R. VILLALOBOS-ARAMBULA

División de Genética

FRANCISCO J. PEREA

División de Medicina Molecular, Centro de Investigación Biomedica de Occidente, CMNO, Instituto Mexicano del Seguro Social, Guadalajara, Mexico

REFERENCES

1. Perea FJ, Esparza MA, Villalobos-Arambula AR, Ibarra B, Old JM: Haplotype analysis of the Mexican frameshift Cd 11 (–T) and –28 A \rightarrow C β -thalassemia alleles. *Am J Hematol* 51:240, 1996.
2. Ropero P, Sanchez J, Gonzalez FA, Armada B, Benito A, Caldeira A, Martín G, Villegas A: Heterogeneidad molecular de la β talasemia. *Sangre (Barc)* 39:365, 1994.
3. Fullerton SM, Harding RM, Boyce AJ, Clegg JB: Molecular and population genetic analysis of allelic sequence diversity at the human β -globin locus. *Proc Natl Acad Sci USA* 91:1805, 1994.